(Q38148233)

29 August 2017

title

The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment (English)

1 reference

29 August 2017

main subject

chronic myeloid leukemia

0 references

2

Susan O'Brien

1 reference

29 August 2017

Nitin Jain

1

1 reference

29 August 2017

language of work or name

1 reference

2 October 2013

1 reference

Expert Review of Hematology

29 August 2017

published in

1 reference

29 August 2017

volume

6

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

575-586

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Ponatinib in refractory Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.835697

10.1586/17474086.2013.835697

21 January 2018

Identifiers

DOI

1 reference

release_zkj2dzdj7vfdfdvrvd6os2mdf4

29 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zkj2dzdj7vfdfdvrvd6os2mdf4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference